Storyline
EpiBiologics lands $107M series b to advance protein-degrading cancer drug
EpiBiologics reported a $107M Series B financing tied to its protein-degrading cancer drug ambitions. Separate coverage also highlighted that the round was led by the venture arms of Johnson & Johnson and Google, underscoring high-profile backing for the company’s targeted protein degradation approach.
Published 2026-01-08 11:00 UTCUpdated 2026-01-08 18:00 UTC
Current brief openSource links open
This current storyline is open here with summary, metadata, source links, continuity context, and full evidence. Paid is for compare-over-time, alerts, exports, and workflow.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
EpiBiologics reported a $107M Series B financing tied to its protein-degrading cancer drug ambitions. Separate coverage also highlighted that the round was led by the venture arms of Johnson & Johnson and Google, underscoring high-profile backing for the company’s targeted protein degradation approach.
Score total
1.3
Momentum 24h
3
Posts
3
Origins
2
Source types
2
Duplicate ratio
33%
Why now
- The $107M Series B was newly reported across multiple outlets in the last 24 hours
- Coverage emphasized notable lead investors, making the round especially newsworthy
Why it matters
- A $107M Series B signals substantial capital availability for protein-degradation oncology plays
- High-profile venture leadership can shape visibility and partnering interest around a platform
- Financing updates help track momentum in targeted protein degradation approaches
Continuity snapshot
- Trend status: insufficient_history.
- Continuity stage: emerging_confirmed.
- Current status: open.
- 3 current source-linked posts are attached to this storyline.
All evidence
All evidence
Protein degradation biotech EpiBiologics has brought in $107 million in a star-studded series B round headed up by Johnson & Johnson's and Google's respective venture arms.
Fierce Biotech (All) · fiercebiotech.com · 2026-01-08 18:00 UTC
EpiBiologics raises $107M for its protein-degrading cancer drug
BioPharma Dive (Latest) · biopharmadive.com · 2026-01-08 11:00 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- Fierce Biotech (All) (1)
- BioPharma Dive (Latest) (1)
Top origin domains (this list)
- fiercebiotech.com (1)
- biopharmadive.com (1)